Gene Techno Science Co.,Ltd. Announces Earnings Results for the Six Months Ended September 30, 2019
November 04, 2019
Share
Gene Techno Science Co.,Ltd. announced earnings results for the six months ended September 30, 2019. For the six months, the company announced net sales of JPY 313 million. Operating loss was JPY 611 million. Net loss was JPY 6,550 million. Net loss per share was JPY 236.95.
Kidswell Bio Corp, formerly Gene Techno Science Co Ltd, is a Japan-based company mainly engaged in the development of biopharmaceuticals. The biosimilar business is engaged in the research, development and provision of filgrastim biosimilar products and pegfilgrastim biosimilar products for cancer, darbepoetin alfa biosimilar products for renal diseases, and ranibizumab biosimilar products for eye diseases. The new biopharmaceutical business is engaged in the research and development of anti-RAMP2 antibodies for cancer and eye diseases, as well as new antibodies. The new biotechnology business is engaged in the development of regenerative medicine products that utilize intracardiac stem cells for pediatric congenital heart diseases, and regenerative medicine products that utilize dental pulp stem cells for cleft lip and palate and intestinal ganglion cell deficiency diseases, as well as the joint research business with universities.
KIDSWELL BIO CORPORATION 
